Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons

Respirology

Volumn 18, Issue 6, 2013, Pages 912-922

  Lee, Shui Shan ^a,b   Meintjes, Graeme ^d   Kamarulzaman, Adeeba ^e   Leung, Chi Chiu ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c DEPARTMENT OF HEALTH   (Hong Kong)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

antiretroviral therapy; immune reconstitution inflammatory syndrome; latent tuberculosis; tuberculosis

Indexed keywords

AMINOGLYCOSIDE; CORTICOSTEROID; CYCLOSERINE; DARUNAVIR PLUS RITONAVIR; DEXAMETHASONE; DOLUTEGRAVIR; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRIDOXINE; QUINOLONE DERIVATIVE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STREPTOMYCIN; TENOFOVIR; TERIZIDONE; UNINDEXED DRUG; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; DIAGNOSTIC TEST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HEPATITIS; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INFECTION; INTERFERON GAMMA RELEASE ASSAY; KIDNEY DYSFUNCTION; LATENT TUBERCULOSIS; LIVER TOXICITY; MENTAL DISEASE; MIXED INFECTION; MORTALITY; NAUSEA; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SCREENING; STRONGYLOIDIASIS; TUBERCULIN TEST; TUBERCULOSIS; VIRUS LOAD;

ANTIRETROVIRAL THERAPY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LATENT TUBERCULOSIS; TUBERCULOSIS;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; COMORBIDITY; DIAGNOSTIC TESTS, ROUTINE; DISEASE MANAGEMENT; DRUG INTERACTIONS; EPIDEMICS; HIV INFECTIONS; HUMANS; LATENT TUBERCULOSIS; TUBERCULOSIS;

EID: 84880835566     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12120     Document Type: Review

References (91)

1. Centers for Disease Control and Prevention (CDC). CDC Grand Rounds: the TB/HIV syndemic. MMWR Morb. Mortal. Wkly Rep. 2012; 61: 484-489.
2. World Health Organization. Global Tuberculosis Report 2012. WHO, Geneva, 2012.
3. Global Report: UNAIDS Report on the Global AIDS Epidemic 2012. UNAIDS, Geneva, 2012.
4. Getahun H, Gunneberg C, Granich R, et al. HIV infection-associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis. 2010; 50 (Suppl. 3): S201-207.
5. Martinson NA, Hoffmann CJ, Chaisson RE,. Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc. Am. Thorac. Soc. 2011; 8: 288-293.
6. Kassa A, Teka A, Shewaamare A, et al. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia. Trans. R. Soc. Trop. Med. Hyg. 2012; 106: 363-370.
7. Jiang X, Lu H, Zhang Y, et al. A cross-sectional study of HIV and tuberculosis coinfection cases in mainland China. South. Med. J. 2008; 101: 914-917.
8. Choun K, Thai S, Pe R, et al. Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia. Trans. R. Soc. Trop. Med. Hyg. 2013; 107: 235-242.
9. Stuckler D, Basu S, McKee M, et al. Mining and risk of tuberculosis in sub-Saharan Africa. Am. J. Public Health 2011; 101: 524-530.
10. Velasco M, Castilla V, Cervero M, et al. The changing pattern of tuberculosis and HIV co-infection in immigrants and Spaniards in the last 20 years. HIV Med. 2008; 9: 227-233.
11. Raghavan S, Alagarasu K, Selvaraj P,. Immunogenetics of HIV and HIV associated tuberculosis. Tuberculosis (Edinb.) 2012; 92: 18-30.
12. Braun MM, Truman BI, Maguire B, et al. Increasing incidence of tuberculosis in a prison inmate population. Association with HIV infection. JAMA 1989; 261: 393-397.
13. Moges B, Amare B, Asfaw F, et al. Prevalence of smear positive pulmonary tuberculosis among prisoners in North Gondar Zone Prison, northwest Ethiopia. BMC Infect. Dis. 2012; 12: 352.
14. Rutta E, Mutasingwa D, Ngallaba S, et al. Tuberculosis in a prison population in Mwanza, Tanzania (1994-1997). Int. J. Tuberc. Lung Dis. 2001; 5: 703-706.
15. Nyangulu DS, Harries AD, Kang'ombe C, et al. Tuberculosis in a prison population in Malawi. Lancet 1997; 350: 1284-1287.
16. Kittikraisak W, Burapat C, Kaewsa-ard S, et al. Factors associated with tuberculosis treatment default among HIV-infected tuberculosis patients in Thailand. Trans. R. Soc. Trop. Med. Hyg. 2009; 103: 59-66.
17. Tseng SH, Jiang DD, Hoi HS, et al. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan. Am. J. Trop. Med. Hyg. 2009; 80: 675-677.
18. Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS ONE 2007; 2: e826.
19. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012; 9: e1001270.
20. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis. 2007; 196 (Suppl. 1): S86-107.
21. Dubrovina I, Miskinis K, Lyepshina S, et al. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? Int. J. Tuberc. Lung Dis. 2008; 12: 756-762.
22. Ritacco V, Lõpez B, Ambroggi M, et al. HIV infection and geographically bound transmission of drug-resistant tuberculosis, Argentina. Emerg. Infect. Dis. 2012; 18: 1802-1810.
23. Sergeev R, Colijn C, Murray M, et al. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med 2012; 4: 135ra67.
24. Dye C, Williams BG, Espinal MA, et al. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-2046.
25. Schutz C, Meintjes G, Almajid F, et al. Clinical management of tuberculosis and HIV-1 co-infection. Eur. Respir. J. 2010; 36: 1460-1481.
26. Chan CK, Alvarez Bognar F, Wong KH, et al. The epidemiology and clinical manifestations of human immunodeficiency virus-associated tuberculosis in Hong Kong. Hong Kong Med. J. 2010; 16: 192-198.
27. Naing C, Mak JW, Maung M, et al. Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis. Lung 2013; 191: 27-34.
28. Department of HIV/AIDS, Stop TB Department, World Health Organization. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings. WHO, Geneva, 2011.
29. Department of HIV/AIDS, Stop TB Department, World Health Organization. Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extrapulmonary Tuberculosis among Adults and Adolescents. Recommendations for HIV-Prevalent and Resource-Constrained Settings. WHO, Geneva, 2007.
30. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369: 2042-2049.
31. Corbett EL, Zezai A, Cheung YB, et al. Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull. World Health Organ. 2010; 88: 13-21.
32. Hanifa Y, Fielding KL, Charalambous S, et al. Tuberculosis among adults starting antiretroviral therapy in South Africa: the need for routine case finding. Int. J. Tuberc. Lung Dis. 2012; 16: 1252-1259.
33. Ho TT, Wong KH, Lee SS,. Low yield of chest radiography in screening for active pulmonary tuberculosis in HIV-infected patients in Hong Kong. Int. J. STD AIDS 1999; 10: 409-412.
34. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011; 8: e1000391.
35. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011; 8: e1001061.
36. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011; 8: e1001067.
37. Lawn SD, Kerkhoff AD, Vogt M, et al. High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J. Acquir. Immune Defic. Syndr. 2012; 60: 289-294.
38. Peter JG, Theron G, Muchinga TE, et al. The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS ONE 2012; 7: e39966.
39. Abimbola TO, Marston BJ, Date AA, et al. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2012; 60: e1-7.
40. Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012; 26: 987-995.
41. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med. 1998; 158: 157-161.
42. Tadokera R, Meintjes G, Skolimowska KH, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur. Respir. J. 2011; 37: 1248-1259.
43. Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin. Infect. Dis. 2013; 56: 450-460.
44. Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis. 2010; 10: 251-261.
45. Barr DA, Ramdial PK,. Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature. BMC Infect. Dis. 2012; 12: 257.
46. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin. Infect. Dis. 2009; 48: e96-107.
47. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341.
48. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int. J. Tuberc. Lung Dis. 2007; 11: 1282-1289.
49. Breton G, Bourgarit A, Pavy S, et al. Treatment for tuberculosis- associated immune reconstitution inflammatory syndrome in 34 HIV-infected patients. Int. J. Tuberc. Lung Dis. 2012; 16: 1365-1370.
50. Huyst V, Lynen L, Bottieau E, et al. Immune reconstitution inflammatory syndrome in an HIV/TB co-infected patient four years after starting antiretroviral therapy. Acta Clin. Belg. 2007; 62: 126-129.
51. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect. Dis. 2008; 8: 516-523.
52. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390.
53. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 2011; 365: 1471-1481.
54. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 2011; 365: 1482-1491.
55. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann. Intern. Med. 2012; 157: 313-324.
56. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 2010; 362: 697-706.
57. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J. Acquir. Immune Defic. Syndr. 2012; 60: 377-383.
58. Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin. Infect. Dis. 2011; 52: 1374-1383.
59. Maartens G, Decloedt E, Cohen K,. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir. Ther. 2009; 14: 1039-1043.
60. van Oosterhout JJ, Kumwenda JJ, Beadsworth M, et al. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir. Ther. 2007; 12: 515-521.
61. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir. Ther. 2008; 13: 529-536.
62. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-539.
63. Bonnet M, Bhatt N, Baudin E, et al. Results of the CARINEMO-ANRS 12 146 randomized trial comparing the efficacy and safety of nevirapine versus efavirenz for treatment of HIV-TB co-infected patients in Mozambique. 6th International AIDS Society Conference, 2011, Rome, Italy. Abstract WELBX05.
64. Lõpez-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin. Pharmacokinet. 2002; 41: 681-690.
65. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir. Ther. 2009; 14: 687-695.
66. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob. Agents Chemother. 2009; 53: 863-868.
67. Kwara A, Lartey M, Sagoe KW, et al. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011; 25: 388-390.
68. Gengiah TN, Holford NH, Botha JH, et al. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur. J. Clin. Pharmacol. 2012; 68: 689-695.
69. Manosuthi W, Sukasem C, Lueangniyomkul A, et al. Impact of Pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob. Agents Chemother. 2013; 57: 1019-1024.
70. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2013. [Accessed 18 February 2013.] Available from URL: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf
71. World Health Orgainsation. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for A Public Health Approach-2010 Revision. WHO, Geneva, 2010. [Accessed 18 February 2013.] Available from URL: http://www.who.int/hiv/pub/arv/adult2010/en/index.html
72. Borand L, Laureillard D, Madec Y, et al. Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg. Antivir. Ther. 2013; 18: 419-423.
73. Ngaimisi E, Mugusi S, Minzi O, et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin. Pharmacol. Ther. 2011; 90: 406-413.
74. Kakuda TN, Schöller-Gyüre M, Hoetelmans RM,. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin. Pharmacokinet. 2011; 50: 25-39.
75. L'homme RF, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 23: 863-865.
76. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob. Agents Chemother. 2004; 48: 1553-1560.
77. Murphy RA, Marconi VC, Gandhi RT, et al. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS ONE 2012; 7: e44793.
78. Decloedt EH, Maartens G, Smith P, et al. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS ONE 2012; 7: e32173.
79. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 2009; 53: 2852-2856.
80. Grinsztejn B, Castro ND, Arnold V, et al. A randomized multicentre open-label trial to estimate the efficacy and safety of two doses of raltegravir (RAL) to efavirenz (EFV) for the treatment of HIV-TB co-infected patients: results of the ANRS 12 180 Reflate TB trial. 19th International AIDS Conference, 2012, Washington DC, USA. Abstract THLBB01.
81. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J. Acquir. Immune Defic. Syndr. 2013; 62: 21-27.
82. Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur. Respir. J. 2011; 37: 690-711.
83. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 1989; 320: 545-550.
84. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 2012; 12: 45-55.
85. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 2010; (1): CD000171.
86. Balcells ME, Thomas SL, Godfrey-Faussett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg. Infect. Dis. 2006; 12: 744-751.
87. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N. Engl. J. Med. 2011; 365: 21-31.
88. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15: 2137-2147.
89. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222.
90. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
91. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N. Engl. J. Med. 2011; 365: 11-20.